Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 1
2016 1
2018 1
2019 1
2021 4
2022 3
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

9 results

Results by year

Filters applied: . Clear all
Page 1
Isoformic PD-1-mediated immunosuppression underlies resistance to PD-1 blockade in hepatocellular carcinoma patients.
Tan Z, Chiu MS, Yang X, Yue M, Cheung TT, Zhou D, Wang Y, Chan AW, Yan CW, Kwan KY, Wong YC, Li X, Zhou J, To KF, Zhu J, Lo CM, Cheng AS, Chan SL, Liu L, Song YQ, Man K, Chen Z. Tan Z, et al. Among authors: cheung tt. Gut. 2023 Aug;72(8):1568-1580. doi: 10.1136/gutjnl-2022-327133. Epub 2022 Nov 30. Gut. 2023. PMID: 36450387
Tumour-infiltrated delta42PD-1(+) T cells likely sustained HCC through toll-like receptors-4-signalling for tumourigenesis. Anti-delta42PD-1 antibody, but not nivolumab, inhibited tumour growth in three murine HCC models. CONCLUSION: Our findings not only revealed a mechan …
Tumour-infiltrated delta42PD-1(+) T cells likely sustained HCC through toll-like receptors-4-signalling for tumourigenesis. Anti-delt …
Recent Advances and Future Prospects in Immune Checkpoint (ICI)-Based Combination Therapy for Advanced HCC.
Dong Y, Wong JSL, Sugimura R, Lam KO, Li B, Kwok GGW, Leung R, Chiu JWY, Cheung TT, Yau T. Dong Y, et al. Among authors: cheung tt. Cancers (Basel). 2021 Apr 18;13(8):1949. doi: 10.3390/cancers13081949. Cancers (Basel). 2021. PMID: 33919570 Free PMC article. Review.
However, outcomes remain undesirable and unpredictable on a patient-to-patient basis. The combination of anti-PD-1/L1 with alternative agents, chiefly cytotoxic T-lymphocyte antigen-4 (CTLA-4) ICIs or agents targeting other oncogenic pathways such as the vascular endotheli …
However, outcomes remain undesirable and unpredictable on a patient-to-patient basis. The combination of anti-PD-1/L1 with alternativ …
Systemic Treatment of Advanced Unresectable Hepatocellular Carcinoma after First-Line Therapy: Expert Recommendations from Hong Kong, Singapore, and Taiwan.
Yau T, Tai D, Chan SL, Huang YH, Choo SP, Hsu C, Cheung TT, Lin SM, Yong WP, Lee J, Leung T, Shum T, Yeung CSY, Tai AY, Law ALY, Cheng AL, Chen LT. Yau T, et al. Among authors: cheung tt. Liver Cancer. 2022 Jun 17;11(5):426-439. doi: 10.1159/000525582. eCollection 2022 Sep. Liver Cancer. 2022. PMID: 36158587 Free PMC article. Review.
In the past 20 years, the systemic treatment landscape of advanced HCC has evolved substantially - from tyrosine kinase inhibitors to immune-oncology agents plus anti-vascular endothelial growth factor agents. The appropriate sequence of therapies has become critical in op …
In the past 20 years, the systemic treatment landscape of advanced HCC has evolved substantially - from tyrosine kinase inhibitors to immune …
Thyroid Immune-Related Adverse Events in Patients with Cancer Treated with anti-PD1/anti-CTLA4 Immune Checkpoint Inhibitor Combination: Clinical Course and Outcomes.
Lui DTW, Lee CH, Tang V, Fong CHY, Lee ACH, Chiu JWY, Leung RCY, Kwok GGW, Li BCW, Cheung TT, Woo YC, Lam KSL, Yau T. Lui DTW, et al. Among authors: cheung tt. Endocr Pract. 2021 Sep;27(9):886-893. doi: 10.1016/j.eprac.2021.01.017. Epub 2021 Feb 11. Endocr Pract. 2021. PMID: 33581327
We evaluated the clinical course and predictors of thyroid irAEs in relation to outcomes of patients with advanced cancer treated with combination anti-PD1/anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA4). ...CONCLUSION: Thyroid irAEs are common in routine c …
We evaluated the clinical course and predictors of thyroid irAEs in relation to outcomes of patients with advanced cancer treated with combi …
Ipilimumab and nivolumab/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors.
Wong JSL, Kwok GGW, Tang V, Li BCW, Leung R, Chiu J, Ma KW, She WH, Tsang J, Lo CM, Cheung TT, Yau T. Wong JSL, et al. Among authors: cheung tt. J Immunother Cancer. 2021 Feb;9(2):e001945. doi: 10.1136/jitc-2020-001945. J Immunother Cancer. 2021. PMID: 33563773 Free PMC article.
No strategies to overcome ICI resistance have been described. We aimed to evaluate the use of ipilimumab and anti-PD-1 ICIs (nivolumab or pembrolizumab) combinations in patients with advanced HCC with progression on prior ICIs. ...
No strategies to overcome ICI resistance have been described. We aimed to evaluate the use of ipilimumab and anti-PD-1 ICIs (nivoluma …
A phase 1 study of pegylated recombinant arginase (PEG-BCT-100) in combination with systemic chemotherapy (capecitabine and oxaliplatin)[PACOX] in advanced hepatocellular carcinoma patients.
Yau T, Cheng PNM, Chiu J, Kwok GGW, Leung R, Liu AM, Cheung TT, Ng CT. Yau T, et al. Among authors: cheung tt. Invest New Drugs. 2022 Apr;40(2):314-321. doi: 10.1007/s10637-021-01178-3. Epub 2021 Nov 4. Invest New Drugs. 2022. PMID: 34735674 Clinical Trial.
Overall median OS was 10.7 months; the median OS was not reached at 19.4 months of follow-up in the 130 mg/m2 cohort. CONCLUSION: The PACOX regimen demonstrated good anti-cancer activity and survival advantage in advanced pre-treated HCC with favourable safety profile. ...
Overall median OS was 10.7 months; the median OS was not reached at 19.4 months of follow-up in the 130 mg/m2 cohort. CONCLUSION: The PACOX …
Validated model for prediction of recurrent hepatocellular carcinoma after liver transplantation in Asian population.
Ma KW, She WH, Chan ACY, Cheung TT, Fung JYY, Dai WC, Lo CM, Chok KSH. Ma KW, et al. Among authors: cheung tt. World J Gastrointest Oncol. 2019 Apr 15;11(4):322-334. doi: 10.4251/wjgo.v11.i4.322. World J Gastrointest Oncol. 2019. PMID: 31040897 Free PMC article.
A predictive model that allows patient stratification according to recurrence risk can help to individualize post-transplant surveillance protocol and guidance of the use of anti-tumor immunosuppressive agents. AIM: To develop a scoring system to predict HCC recurrence aft …
A predictive model that allows patient stratification according to recurrence risk can help to individualize post-transplant surveillance pr …
Prognostic influence of spontaneous tumor rupture on hepatocellular carcinoma after interval hepatectomy.
Chan AC, Dai JW, Chok KS, Cheung TT, Lo CM. Chan AC, et al. Among authors: cheung tt. Surgery. 2016 Feb;159(2):409-17. doi: 10.1016/j.surg.2015.07.020. Epub 2015 Aug 18. Surgery. 2016. PMID: 26294087

RESULTS: Ruptured HCC had substantially worse survival than nonruptured tumor (5-year overall survival: 22.3% vs 53.4% P < .001). Anti-HCV status (hazard ratio [HR]: 3.225 confidence interval [95% CI]: 1.175-8.847, P = .023), platelet count (HR: 1.003, CI 1.0001-1.006,

…

RESULTS: Ruptured HCC had substantially worse survival than nonruptured tumor (5-year overall survival: 22.3% vs 53.4% P < .001). Anti

…
Blocking CDK1/PDK1/β-Catenin signaling by CDK1 inhibitor RO3306 increased the efficacy of sorafenib treatment by targeting cancer stem cells in a preclinical model of hepatocellular carcinoma.
Wu CX, Wang XQ, Chok SH, Man K, Tsang SHY, Chan ACY, Ma KW, Xia W, Cheung TT. Wu CX, et al. Among authors: cheung tt. Theranostics. 2018 Jun 13;8(14):3737-3750. doi: 10.7150/thno.25487. eCollection 2018. Theranostics. 2018. PMID: 30083256 Free PMC article.
Mechanistic and functional studies silencing CDK1 with shRNA and RO3306 combined with sorafenib abolished oncogenic function via downregulating CDK1, with downstream PDK1 and beta-Catenin inactivation. Conclusion: Anti-CDK1 treatment can boost sorafenib antitumor responses …
Mechanistic and functional studies silencing CDK1 with shRNA and RO3306 combined with sorafenib abolished oncogenic function via downregulat …